About us

A+ Science is a Contract Research Organisation (CRO) with long experience of services in clinical trials for pharmaceuticals (Phase I-IV) as well as medical devices. We also have experience in conducting non-interventional and registry trials.

We have long experience since 1997 and work in broad spectra of therapeutic areas in Sweden, Denmark, Norway and Finland. Through our close collaboration with our CRO partners, we also cover Germany, Spain, Portugal, Poland, Check Republic, Italy, Slovenia, Slovakia, Russia, Latvia, Ukraine, Georgia, Estonia, Belarus, Bulgaria, Croatia, Hungary, Kazakhstan, Lithuania, Montenegro, Romania, Serbia and Israel. 

Our staff is familiar with responsibilities within project management and monitoring which could range from small complex to multicenter trials.

Through close cooperation and continuous dialogue with customers, our services can be customised according to your requirements. By being flexible we can provide a complete solution or support within specific areas and activities.

Among our customers are pharmaceuticals, generic, biotech and medical device companies, as well as Clinical Research Organisations (CROs) located in Sweden, Europe and USA.

Through medical expertise, critical knowledge and many years of experience we can offer cost-effective services during clinical development as well as services after marketing authorisation.

A+ Science is member of SwedenBIO, Medicon Valley Alliance (MVA),  ASCRO and LIF.

Since December 2013, A+ Science is a CRO run by its employees. Our vision is to Earn Trust - Make Difference.

What is a clinical CRO?

A Clinical CRO (Contract Research Organisation) is a service organisation that provides support to the pharmaceutical and biotech industry as well as medical devices. CROs contribute to the development of new medicines that improve health and quality of life for patients. That work is mostly summarised in an activity called clinical trials.

Clinical Trials

Clinical trials are used to determine the safety and efficacy of new treatments in patients. The new treatment is tested in several stages and must be beneficial for patients to be accepted and marketed. A clinical trial cannot start without the approval of independent ethics committees and competent authorities.